Rapsgatan 7E
Uppsala
Sweden
46 1 87 80 88 00
https://www.orexo.com
Sector(s): Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Full-time employees: 118
Name | Title | Pay | Exercised | Year born |
---|---|---|---|---|
Mr. Nikolaj Sorensen | President & CEO | 5.78M | N/A | 1972 |
Mr. Fredrik Jarrsten | Executive VP & CFO | N/A | N/A | 1967 |
Ms. Cecilia Coupland | Senior VP & Head of Operations | N/A | N/A | 1976 |
Lena Wange | Investor Relations & Communications Director | N/A | N/A | N/A |
Mr. Robert Ronn | Senior VP and Head of R&D | N/A | N/A | 1976 |
Dr. Edward Kim M.B.A., M.D. | Chief Medical Officer | N/A | N/A | N/A |
Mr. Robert A. Deluca | President of Orexo US Inc | N/A | N/A | 1961 |
Mr. Jesper Lind | Advisor | N/A | N/A | 1960 |
Orexo AB (publ), a specialty pharmaceutical company, develops and commercializes pharmaceuticals and digital therapies in the United States, European Union, and internationally. Its products include Zubsolv tablets for the treatment of opioid use disorder; Abstral for the treatment of breakthrough pain in cancer patients; and Edluar for the treatment of insomnia. The company is also developing OX124 for opioid overdose; OX125 for rescue medication and opioid overdose; OX640 for emergency treatment of allergic reactions; and OX-MPI for the treatment of endometriosis. In addition, its digital therapies include deprexis for the treatment of depression; vorvida for alcohol management; and modia for opioid use disorder. Orexo AB (publ) was incorporated in 1994 and is headquartered in Uppsala, Sweden.
Orexo AB (publ)’s ISS governance QualityScore as of 1 December 2023 is 5. The pillar scores are Audit: 8; Board: 1; Shareholder rights: 4; Compensation: 10.